23.03.2018 STADA Arzneimittel AG  DE0007251803

DGAP-Adhoc: STADA Arzneimittel AG: Executive Board of STADA Arzneimittel AG decides to file application related to change of sub-segment of the stock exchange


 
DGAP-Ad-hoc: STADA Arzneimittel AG / Key word(s): Miscellaneous STADA Arzneimittel AG: Executive Board of STADA Arzneimittel AG decides to file application related to change of sub-segment of the stock exchange 23-March-2018 / 21:00 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Bad Vilbel, March 23, 2018, 07.25pm - The Executive Board of STADA Arzneimittel AG (STADA) decided today after the close of the stock exchange to apply to the management board of the Frankfurt Stock Exchange pursuant to § 57 of the "Exchange Rules for the Frankfurter Wertpapierbörse" shortly for the revocation of admission of the STADA shares to the sub-segment of the regulated market with additional obligations arising from the admission (Prime Standard), whereby the STADA shares will be listed on the regulated market (General Standard) for trading ex officio. By changing the sub-segment of the stock exchange the company's post-listing obligations like certain reporting and publication requirements will fall away. This will avoid substantial effort and assist the Company in cost-saving and streamlining processes. The withdrawal of the listing becomes effective three months after the publication of the withdrawal decision by the Management of the Frankfurt Stock Exchange on the internet ( www.deutsche-boerse.com). Contact: STADA Arzneimittel AG / Investor Relations / Leslie Iltgen / Stadastraße 2-18 / 61118 Bad Vilbel / Tel.: +49 (0) 6101 603-173 / Fax: +49 (0) 6101 603-215 / E-Mail: [email protected] or visit us online on www.stada.de. --------------------------------------------------------------------------- 23-March-2018 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de --------------------------------------------------------------------------- Language: English Company: STADA Arzneimittel AG Stadastraße 2-18 61118 Bad Vilbel Germany Phone: +49 (0)6101 603- 113 Fax: +49 (0)6101 603- 506 E-mail: [email protected] Internet: www.stada.de ISIN: DE0007251803, DE0007251845, WKN: 725180, 725184, Indices: MDAX Listed: Regulated Market in Dusseldorf, Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange End of Announcement DGAP News Service --------------------------------------------------------------------------- 668369 23-March-2018 CET/CEST


Die wichtigsten Finanzdaten auf einen Blick
  2015 2016 2017 2018 2019 2020 2021e
Umsatzerlöse1 0,00 0,00 0,00 0,00 0,00 0,00 0,00
EBITDA1,2 0,00 0,00 0,00 0,00 0,00 0,00 0,00
EBITDA-Marge3 0,00 0,00 0,00 0,00 0,00 0,00 0,00
EBIT1,4 0,00 0,00 0,00 0,00 0,00 0,00 0,00
EBIT-Marge5 0,00 0,00 0,00 0,00 0,00 0,00 0,00
Jahresüberschuss1 0,00 0,00 0,00 0,00 0,00 0,00 0,00
Netto-Marge6 0,00 0,00 0,00 0,00 0,00 0,00 0,00
Cashflow1,7 0,00 0,00 0,00 0,00 0,00 0,00 0,00
Ergebnis je Aktie8 0,00 0,00 0,00 0,00 0,00 0,00 0,00
Dividende8 0,00 0,00 0,00 0,00 0,00 0,00 0,00
Quelle: boersengefluester.de und Firmenangaben

1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer:

INVESTOR-INFORMATIONEN
©boersengefluester.de
WKN Kurs in € Einschätzung Börsenwert in Mio. €
0,000 0,00
KGV 2022e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
0,00 0,00 0,00 0,00
KBV KCV KUV EV/EBITDA
0,00 0,00 0,00 0,00
Dividende '19 in € Dividende '20e in € Div.-Rendite '20e
in %
Hauptversammlung
0,00 0,00 0,00
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
0,00% 0,00% 0,00% 0,00%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu STADA Arzneimittel AG  ISIN: DE0007251803 können Sie bei DGAP abrufen

Gesundheit , 725180 , SAZ , XETR:SAZ